818 related articles for article (PubMed ID: 28869450)
21. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
[TBL] [Abstract][Full Text] [Related]
22. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
[TBL] [Abstract][Full Text] [Related]
23. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
24. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
26. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
27. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
28. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
31. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
[TBL] [Abstract][Full Text] [Related]
32. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
[TBL] [Abstract][Full Text] [Related]
33. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
34. MR Elastography Analysis of Glioma Stiffness and
Pepin KM; McGee KP; Arani A; Lake DS; Glaser KJ; Manduca A; Parney IF; Ehman RL; Huston J
AJNR Am J Neuroradiol; 2018 Jan; 39(1):31-36. PubMed ID: 29074637
[TBL] [Abstract][Full Text] [Related]
35. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
37. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
Shibahara I; Sonoda Y; Kanamori M; Saito R; Yamashita Y; Kumabe T; Watanabe M; Suzuki H; Kato S; Ishioka C; Tominaga T
Int J Clin Oncol; 2012 Dec; 17(6):551-61. PubMed ID: 21971842
[TBL] [Abstract][Full Text] [Related]
38. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
Int J Clin Exp Pathol; 2013; 6(1):31-40. PubMed ID: 23236540
[TBL] [Abstract][Full Text] [Related]
39. Mean apparent propagator-MRI in evaluation of glioma grade, cellular proliferation, and IDH-1 gene mutation status.
Sun Y; Su C; Deng K; Hu X; Xue Y; Jiang R
Eur Radiol; 2022 Jun; 32(6):3744-3754. PubMed ID: 35076759
[TBL] [Abstract][Full Text] [Related]
40. Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study.
Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]